Abstract
Fecal incontinence is defined as greater than 1 month of uncontrolled passage of fecal material or gas in a person age 4 years or older, who previously achieved control. Treatment of fecal incontinence can be challenging and should be individualized. This chapter discusses the general approaches to the management of fecal incontinence with a focus on nonoperative management. More invasive approaches such as replacement, repair, augmentation, stimulation, and fecal diversion are outlined.
Commentary by Tracy L. Hull, Cleveland Clinic, Department of Colon and Rectal Surgery, Cleveland, OH, USA
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Paquette IM, Varma MG, Kaiser AM, Steele SR, Rafferty JF. The American Society of Colon and Rectal Surgeons’ clinical practice guideline for the treatment of fecal incontinence. Dis Colon Rectum. 2015;58(7):623–36.
Ditah I, Devaki P, Luma HN, et al. Prevalence, trends, and risk factors for fecal incontinence in United States adults, 2005-2010. Clin Gastroenterol Hepatol. 2014;12(4):636–43.
Goode PS, Burgio KL, Halli AD, et al. Prevalence and correlates of fecal incontinence in community-dwelling older adults. J Am Geriatr Soc. 2005;53(4):629–35.
Markland AD, Goode PS, Burgio KL, et al. Incidence and risk factors for fecal incontinence in black and white older adults: a population-based study. J Am Geriatr Soc. 2010;58(7):1341–6.
Whitehead WE, Borrud L, Goode PS, et al. Fecal incontinence in US adults: epidemiology and risk factors. Gastroenterology. 2009;137(2):512–7, 517.e1–2.
Nelson RL. Epidemiology of fecal incontinence. Gastroenterology. 2004;126(1 Suppl 1):S3–7.
Menees SB, Almario CV, Spiegel BMR, Chey WD. Prevalence of and factors associated with fecal incontinence: results from a population-based survey. Gastroenterology. 2018;154(6):1672–1681.e3.
Brown HW, Wexner SD, Segall MM, Brezoczky KL, Lukacz ES. Accidental bowel leakage in the mature women’s health study: prevalence and predictors. Int J Clin Pract. 2012;66(11):1101–8.
Pinto RA, Sands DR. Surgery and sacral nerve stimulation for constipation and fecal incontinence. Gastrointest Endosc Clin N Am. 2009;19(1):83–116, vi–vii.
Townsend MK, Matthews CA, Whitehead WE, Grodstein F. Risk factors for fecal incontinence in older women. Am J Gastroenterol. 2013;108(1):113–9.
Bharucha AE, Fletcher JG, Melton LJ 3rd, Zinsmeister AR. Obstetric trauma, pelvic floor injury and fecal incontinence: a population-based case-control study. Am J Gastroenterol. 2012;107(6):902–11.
Jorge JM, Wexner SD. Etiology and management of fecal incontinence. Dis Colon Rectum. 1993;36(1):77–97.
Brown HW, Wexner SD, Lukacz ES. Factors associated with care seeking among women with accidental bowel leakge. Female Pelvic Med Reconstr Surg. 2013;19(2):66–71.
Brown HW, Wexner SD, Segall MM, Brezoczky KL, Lukacz ES. Quality of life impact in women with accidental bowel leakage. Int J Clin Pract. 2012;66(11):1109–16.
Perry S, Shaw C, McGrother C, et al. Prevalence of faecal incontinence in adults aged 40 years or more living in the community. Gut. 2002;50(4):480–4.
Roberts RO, Jacobsen SJ, Reilly WT, Pemberton JH, Lieber MM, Talley NJ. Prevalence of combined fecal and urinary incontinence: a community-based study. J Am Geriatr Soc. 1999;47(7):837–41.
Shirran E, Brazzelli M. Absorbent products for the containment of urinary and/or faecal incontinence in adults. Cochrane Database Syst Rev. 2000;(2):CD001406.
Wald A. Diagnosis and management of fecal incontinence. Curr Gastroenterol Rep. 2018;20(3):9.
Rosier PF, Gajewski JB, Sand PK, et al. Executive summary: The International Consultation on Incontinence 2008--Committee on: “Dynamic Testing”; for urinary incontinence and for fecal incontinence. Part 1: Innovations in urodynamic techniques and urodynamic testing for signs and symptoms of urinary incontinence in female patients. Neurourol Urodyn. 2010;29(1):140–5.
Palmer KR, Corbett CL, Holdsworth CD. Double-blind cross-over study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhea. Gastroenterology. 1980;79(6):1272–5.
Read MG, Krejs GJ, Hendler RS, Davis G, Fordtran JS. A report of five patients with large-volume secretory diarrhea but no evidence of endocrine tumor or laxative abuse. Dig Dis Sci. 1982;27(3):193–201.
Sun WM, Read NW, Verlinden M. Effects of loperamide oxide on gastrointestinal transit time and anorectal function in patients with chronic diarrhoea and faecal incontinence. Scand J Gastroenterol. 1997;32(1):34–8.
Cheetham M, Brazzelli M, Norton C, Glazener CM. Drug treatment for faecal incontinence in adults. Cochrane Database Syst Rev. 2003;(3):CD002116.
Remes-Troche JM, Ozturk R, Philips C, Stessman M, Rao SS. Cholestyramine – a useful adjunct for the treatment of patients with fecal incontinence. Int J Color Dis. 2008;23(2):189–94.
Wedlake L, A’Hern R, Russell D, Thomas K, Walters JR, Andreyev HJ. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2009;30(7):707–17.
Santora GA, Eitan BZ, Pryde A, Bartolo DC. Open study of low-dose amitriptyline in the treatment of patients with idiopathic fecal incontinence. Dis Colon Rectum. 2000;43(12):1676–81.
Bharucha AE, Fletcher JG, Camilleri M, Edge J, Carlson P, Zinsmeister AR. Effects of clonidine in women with fecal incontinence. Clin Gastroenterol Hepatol. 2014;12(5):843–851.e2.
Bharucha AE, Seide BM, Zinsmeister AR. The effects of clonidine on symptoms and anorectal sensorimotor function in women with faecal incontinence. Aliment Pharmacol Ther. 2010;32(5):681–8.
Heymen S, Scarlett Y, Jones K, Ringel Y, Drossman D, Whitehead WE. Randomized controlled trial shows biofeedback to be superior to pelvic floor exercises for fecal incontinence. Dis Colon Rectum. 2009;52(10):1730–7.
Maeda Y, Laurberg S, Norton C. Perianal injectable bulking agents as treatment for faecal incontinence in adults. Cochrane Database Sys Rev. 2010;(5):CD007959.
Danielson J, Karlbom U, Wester T, Graf W. Efficacy and quality of life 2 years after treatment for faecal incontinence with injectable bulking agents. Tech Coloproctol. 2013;17(4):389–95.
Maeda Y, Laurberg S, Norton C. Perianal injectable bulking agents as treatment for faecal incontinence in adults. Cochrane Database Syst Rev. 2013;(2):CD007959.
Richter HE, Matthews CA, Muir T, et al. A vaginal bowel-control system for the treatment of fecal incontinence. Obstet Gynecol. 2015;125(3):540–7.
Deutekom M, Dobben AC. Plugs for containing faecal incontinence. Cochrane Database Syst Rev. 2015;(7):CD005086.
Lukacz ES, Segall MM, Wexner SD. Evaluation of an anal insert device for the conservative management of fecal incontinence. Dis Colon Rectum. 2015;58(9):892–8.
Leroi AM, Siproudhis L, Damon EH, et al. Transcutaneous electrical tibial stimuliation in the treatment of fecal incontinence: a randomized trial (CONSORT 1a). Am J Gastroenterol. 2012;107(12):1888–96.
Horrocks EJ, Bremner SA, Stevens N, et al. Double-blind randomised controlled trial of percutaneous tibial nerve stimulation versus sham electrical stimulation in the treatment of faecal incontinence: CONtrol of Faecal Incontinence using Distal NeuromodulaTion (the CONFIDeNT trial). Health Technol Assess. 2015;19(77):1–164.
Horrocks EJ, Chadi SA, Stevens NJ, Wexner SD, Knowles CH. Factors associated with efficacy of percutaneous tibial nerve stimulation for fecal incontinence, based on post-hoc analysis of data from a randomized trial. Clin Gastroenterol Hepatol. 2017;15(12):1915–1921.e2.
Thin NN, Horrocks EJ, Hotouras A, et al. Systematic review of the clinical effectiveness of neuromodulation in the treatment of faecal incontinence. Br J Surg. 2013;100(11):1430–47.
Horrocks EJ, Thin N, Thaha MA, Taylor SJ, Norton C, Knowles CH. Systematic review of tibial nerve stimulation to treat faecal incontinence. Br J Surg. 2014;101(5):457–68.
Colquhoun P, Kaiser R, Weiss EG, et al. Correlating the Fecal Incontinence Quality-of-Life Score and the SF-36 to a proposed Ostomy Function Index in patients with a stoma. Ostomy Wound Manage. 2006;52(12):68–74.
Norton C, Burch J, Kamm MA. Patients’ views of a colostomy for fecal incontinence. Dis Colon Rectum. 2005;48(5):1062–9.
Graf W, Mellgren A, Matzel KE, Hull T, Johansson C, Bernstein M, et al. Efficacy of dextranomer in stabilised hyaluronic acid for treatment of faecal incontinence: a randomised, sham-controlled trial. Lancet. 2011;377(9770):997–1003. PubMed PMID: 21420555.
Mellgren A, Matzel KE, Pollack J, Hull T, Bernstein M, Graf W, et al. Long-term efficacy of NASHA Dx injection therapy for treatment of fecal incontinence. Neurogastroenterol Motil. 2014;26(8):1087–94. PubMed PMID: 24837493. Pubmed Central PMCID: 4371654.
Danielson J, Karlbom U, Sonesson AC, Wester T, Graf W. Submucosal injection of stabilized nonanimal hyaluronic acid with dextranomer: a new treatment option for fecal incontinence. Dis Colon Rectum. 2009;52(6):1101–6. PubMed PMID: 19581853.
Dodi G, Jongen J, de la Portilla F, Raval M, Altomare DF, Lehur PA. An open-label, noncomparative, multicenter study to evaluate efficacy and safety of NASHA/Dx gel as a bulking agent for the treatment of fecal incontinence. Gastroenterol Res Pract. 2010;2010:467136. PubMed PMID: 21234379. Pubmed Central PMCID: 3017894.
Schwandner O, Brunner M, Dietl O. Quality of life and functional results of submucosal injection therapy using dextranomer hyaluronic acid for fecal incontinence. Surg Innov. 2011;18(2):130–5. PubMed PMID: 21245071.
Ratto C, Buntzen S, Aigner F, Altomare DF, Heydari A, Donisi L, et al. Multicentre observational study of the Gatekeeper for faecal incontinence. Br J Surg. 2016;103(3):290–9. PubMed PMID: 26621029. Pubmed Central PMCID: 5063193.
Trenti L, Biondo S, Noguerales F, Nomdedeu J, Coret A, Scherer R, et al. Outcomes of Gatekeeper(TM) prosthesis implantation for the treatment of fecal incontinence: a multicenter observational study. Tech Coloproctol. 2017;21(12):963–70.
de la Portilla F, Reyes-Diaz ML, Maestre MV, Jimenez-Rodriguez RM, Garcia-Cabrera AM, Vazquez-Monchul JM, et al. Ultrasonographic evidence of Gatekeeper prosthesis migration in patients treated for faecal incontinence: a case series. Int J Color Dis. 2017;32(3):437–40. PubMed PMID: 28054134.
Efron JE, Corman ML, Fleshman J, Barnett J, Nagle D, Birnbaum E, et al. Safety and effectiveness of temperature-controlled radio-frequency energy delivery to the anal canal (Secca procedure) for the treatment of fecal incontinence. Dis Colon Rectum. 2003;46(12):1606–16; discussion 16–8. PubMed PMID: 14668584.
Felt-Bersma RJ, Szojda MM, Mulder CJ. Temperature-controlled radiofrequency energy (SECCA) to the anal canal for the treatment of faecal incontinence offers moderate improvement. Eur J Gastroenterol Hepatol. 2007;19(7):575–80. PubMed PMID: 17556904.
Lefebure B, Tuech JJ, Bridoux V, Gallas S, Leroi AM, Denis P, et al. Temperature-controlled radio frequency energy delivery (Secca procedure) for the treatment of fecal incontinence: results of a prospective study. Int J Color Dis. 2008;23(10):993–7.
Kim DW, Yoon HM, Park JS, Kim YH, Kang SB. Radiofrequency energy delivery to the anal canal: is it a promising new approach to the treatment of fecal incontinence? Am J Surg. 2009;197(1):14–8.
Ruiz D, Pinto RA, Hull TL, Efron JE, Wexner SD. Does the radiofrequency procedure for fecal incontinence improve quality of life and incontinence at 1-year follow-up? Dis Colon Rectum. 2010;53(7):1041–6. PubMed PMID: 20551757.
Abbas MA, Tam MS, Chun LJ. Radiofrequency treatment for fecal incontinence: is it effective long-term? Dis Colon Rectum. 2012;55(5):605–10. PubMed PMID: 22513440.
Lam TJ, Visscher AP, Meurs-Szojda MM, Felt-Bersma RJ. Clinical response and sustainability of treatment with temperature-controlled radiofrequency energy (Secca) in patients with faecal incontinence: 3 years follow-up. Int J Color Dis. 2014;29(6):755–61. PubMed PMID: 24805249.
Takahashi-Monroy T, Morales M, Garcia-Osogobio S, Valdovinos MA, Belmonte C, Barreto C, et al. SECCA procedure for the treatment of fecal incontinence: results of five-year follow-up. Dis Colon Rectum. 2008;51(3):355–9. PubMed PMID: 18204954.
Visscher AP, Lam TJ, Meurs-Szojda MM, Felt-Bersma RJF. Temperature-controlled delivery of radiofrequency energy in fecal incontinence: a randomized sham-controlled clinical trial. Dis Colon Rectum. 2017;60(8):860–5. PubMed PMID: 28682972.
Takahashi T, Garcia-Osogobio S, Valdovinos MA, Belmonte C, Barreto C, Velasco L. Extended two-year results of radio-frequency energy delivery for the treatment of fecal incontinence (The Secca Procedure). Dis Colon Rectum. 2003;46(6):711–5.
Takahashi T, Garcia-Osogobio S, Valdovinos MA, Mass W, Jimenez R, Jauregui LA, Bobadilla J, Belmonte C, Edelstein PS, Utley DS. Radio-frequency energy delivery to the anal canal for the treatment of fecal incontinence. Dis Colon Rectum. 2002;45(7):915–22.
Walega P, Romaniszyn M, Siarkiewicz B, Zelazny D. Dynamic versus adynamic graciloplasty in treatment of end-stage fecal incontinence: is the implantation of the pacemaker really necessary? 12-month follow-up in a clinical, physiological, and functional study. Gastroenterol Res Pract. 2015;2015:698516.
Alavi K, Chan S, Wise P, Kaiser AM, Sudan R, Bordeianou L. Fecal incontinence: etiology, diagnosis, and management. J Gastrointest Surg. 2015;19(10):1910–21. PubMed PMID: 26268955.
Freeman A, Menees S. Fecal incontinence and pelvic floor dysfunction in women: a review. Gastroenterol Clin North Am. 2016;45(2):217–37.
Murad-Regadas SM, Regadas FSP, Regadas Filho FSP, Mendonça Filho JJ, Andrade Filho RS, Vilarinho ADS. Predictors of unsuccessful treatment for fecal incontinence biofeedback in females. Arq Gastroenterol. 2019;56(1):61–5.
Wald A. Diagnosis and management of fecal incontinence. Curr Gastroenterol Rep. 2018;20(3):9.
Sanagapalli S, Harrington S, Zarate-Lopez N, Emmanuel A. Posterior tibial nerve stimulation for the treatment of fecal incontinence following obstetric anal sphincter injury. Neuromodulation. 2018;21(7):688–93.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Commentary
Commentary
Fecal incontinence (FI) as outlined in this chapter is not uncommon. The etiology is multifactorial, and treatment is individualized for each patient. Therefore, a comprehensive history is the first step in caring for this group of patients. Physical exam further refines treatment possibilities [63].
Some FI results from inflammatory conditions like ulcerative colitis. Treatment of the primary inflammatory process is the initial therapy. Otherwise, most treatment recommendations begin with a combination of nonsurgical approaches, which are discussed in detail in this chapter. The goal should aim toward total continence. Many studies determine successful results as 50% reduction in incontinent episodes. While a 50% reduction may be an improvement, any accidental episodes of FI can be humiliating and demoralizing.
Loose stools are a factor for many patients with FI, and strategies to minimize diarrhea are part of most recommendations. As mentioned, anal skin care with protective barrier creams is sometimes a forgotten component of treatment [64]. Physical therapy utilizing auditory and/or visual feedback emphasizes retraining for improved anal strength, pelvic coordination, and optimization of rectal sensitivity. This therapy can be operator dependent and time intensive to produce an acceptable outcome. Enemas or rectal washout is also a treatment strategy that may be successfully utilized for selected patients who are motivated to use this therapy [65, 66]. As outlined in the chapter, a combination of these treatments is part of the individual approach.
To further optimize quality of life, other nonsurgical approaches may be considered. While insertion of devices into the vagina in women or anal inserts seem like attractive options to prevent stool from being expelled at unwanted times, both success and tolerance have been suboptimal [66].
With the success of sacral nerve modulation, percutaneous tibial nerve stimulation seems like an attractive less invasive treatment that should stimulate similar nerve pathways. Results have not been straightforward, but as discussed in the chapter, selective patients may benefit [67].
Nonsurgical therapies are overall safe and do not burn bridges for other therapies. For patients who have failed all treatment options or are not candidates for other therapies, fecal diversion allows patients the ability to leave home, work, and attend social functions. A stoma should not be viewed as a failure, but instead as a means to improve quality of life in this group of patients [66].
As mentioned in this chapter, critical examination of studies regarding FI is essential when determining efficacy of therapy. As with many areas of pelvic floor research, patient selection for studies may not appropriately compare like patients, especially those with FI. FI is difficult to treat. Appraisal of the characteristics of patient included in studies and the primary aim should be scrutinized before fully dismissing a treatment with minimal risk to patients with FI.
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Lao, V.V., Sands, D.R. (2021). Treatment for Fecal Incontinence: Nonsurgical Approaches. In: Kobashi, K.C., Wexner, S.D. (eds) Female Pelvic Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-54839-1_11
Download citation
DOI: https://doi.org/10.1007/978-3-030-54839-1_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-54838-4
Online ISBN: 978-3-030-54839-1
eBook Packages: MedicineMedicine (R0)